PSMB6 Human
Description
PSMB6 is fused to a 21 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques.
Product Specs
Product Science Overview
Proteasome Subunit Beta Type 6 (PSMB6), also known as Proteasome 20S Subunit Beta 6, is a crucial component of the proteasome complex, which plays a vital role in the degradation of intracellular proteins. This article delves into the structure, function, and significance of PSMB6, particularly focusing on its human recombinant form.
PSMB6 is a protein-coding gene located on chromosome 17 in humans . The protein itself is composed of 205 amino acids and has a molecular weight of approximately 22 kDa . It is a part of the 20S core proteasome complex, which consists of four stacked rings forming a barrel-like structure. The two outer rings are composed of alpha subunits, while the two inner rings consist of beta subunits, including PSMB6 .
The primary function of PSMB6 is to participate in the proteolytic degradation of most intracellular proteins. This process is ATP-dependent and involves the ubiquitin-proteasome pathway . The proteasome complex, including PSMB6, is responsible for degrading misfolded, damaged, or unneeded proteins, thereby maintaining cellular homeostasis . Additionally, PSMB6 plays a role in various cellular processes such as cell cycle regulation, signal transduction, and immune responses .
Recombinant PSMB6 is produced using recombinant DNA technology, where the PSMB6 gene is cloned and expressed in a suitable host system, such as Escherichia coli . This allows for the production of large quantities of the protein, which can be used for various research and therapeutic purposes. Recombinant PSMB6 is often used in studies related to protein degradation, proteasome function, and the development of proteasome inhibitors for therapeutic applications .
Mutations or dysregulation of PSMB6 have been associated with various diseases, including Parkinson’s disease . The protein’s involvement in the degradation of intracellular proteins makes it a potential target for therapeutic interventions in diseases characterized by protein aggregation and misfolding . Furthermore, the study of recombinant PSMB6 can provide insights into the development of drugs that modulate proteasome activity, offering potential treatments for cancer and neurodegenerative disorders .
